Following Neurocrine's (NBIX) announcement of FDA approval of Ingrezza, or valbenazine, for adults with Tardive Dyskinesia, Leerink analyst Paul Matteis says that the language in the label looks to be a best-case scenario for the company as it outlines few safety risks and does not contain a black box warning for increased risk of suicidality. The analyst believes the latter adds to valbenazine's advantages over Teva's (TEVA) SD-809. Matteis moved his odds of FDA approval from 90% to 100%, reiterated an Outperform rating on Neurocrine's stock and raised his price target on the shares to $68 from $65.